Molecular Psychiatry
https://doi.org/10.1038/s41380-020-00969-z
ARTICLE
Cognitive functioning throughout adulthood and illness stages in
individuals with psychotic disorders and their unaffected siblings
Eva Velthorst 1,2,3 Josephine Mollon 4 Robin M. Murray 5 Lieuwe de Haan3,6 Inez Myin Germeys7
David C. Glahn4 Celso Arango8 Els van der Ven9,10 Marta Di Forti11,12 Miguel Bernardo13 Sinan Guloksuz10,14
Philippe Delespaul10,15 Gisela Mezquida13 Silvia Amoretti 13 Julio Bobes 16 Pilar A. Saiz16
María Paz García-Portilla16 José Luis Santos16,17,18 Estela Jiménez-López16,19 Julio Sanjuan20 Eduardo J. Aguilar20
Manuel Arrojo21 Angel Carracedo22,23 Gonzalo López16 Javier González-Peñas16 Mara Parellada8
Cem Atbaşoğlu 24 Meram Can Saka24 Alp Üçok25 Köksal Alptekin26,27 Berna Akdede26 Tolga Binbay26
Vesile Altınyazar28 Halis Ulaş26 Berna Yalınçetin27 Güvem Gümüş-Akay29,30 Burçin Cihan Beyaz31 Haldun Soygür32
Eylem Şahin Cankurtaran33 Semra Ulusoy Kaymak34 Nadja P. Maric35 Marina M. Mihaljevic35
Sanja Andric Petrovic36 Tijana Mirjanic37 Cristina Marta Del-Ben 38 Laura Ferraro5 Charlotte Gayer-Anderson39
Peter B. Jones 40 Hannah E. Jongsma40,41 James B. Kirkbride 41 Caterina La Cascia42 Antonio Lasalvia43
Sarah Tosato 43 Pierre-Michel Llorca 44 Paulo Rossi Menezes 45 Craig Morgan39,46 Diego Quattrone11
Marco Menchetti47 Jean-Paul Selten10,48 Andrei Szöke49 Ilaria Tarricone50 Andrea Tortelli51 Philip McGuire5
Lucia Valmaggia52 Matthew J. Kempton5 Mark van der Gaag53 Anita Riecher-Rössler54 Rodrigo A. Bressan 55
Neus Barrantes-Vidal56,57 Barnaby Nelson58,59 Patrick McGorry58,60 Chris Pantelis 60 Marie-Odile Krebs61
Stephan Ruhrmann62 Gabriele Sachs63 Bart P. F. Rutten 10 Jim van Os5,10,64 Behrooz Z. Alizadeh 65,66
Therese van Amelsvoort10 Agna A. Bartels-Velthuis66 Richard Bruggeman66,67 Nico J. van Beveren68,69,70
Jurjen J. Luykx64,71,72 Wiepke Cahn64,73 Claudia J. P. Simons 10,74 Rene S. Kahn 1,75 Frederike Schirmbeck3,6
Ruud van Winkel10,76 EU-GEI High Risk Study Abraham Reichenberg1,2
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
1234567890();,:
●
●
●
●
●
●
●
●
●
●
●
1234567890();,:
●
●
●
●
●
●
●
Received: 19 August 2020 / Revised: 3 November 2020 / Accepted: 18 November 2020
© The Author(s), under exclusive licence to Springer Nature Limited 2021
Abstract
Important questions remain about the profile of cognitive impairment in psychotic disorders across adulthood and illness
stages. The age-associated profile of familial impairments also remains unclear, as well as the effect of factors, such as
symptoms, functioning, and medication. Using cross-sectional data from the EU-GEI and GROUP studies, comprising 8455
participants aged 18 to 65, we examined cognitive functioning across adulthood in patients with psychotic disorders (n =
2883), and their unaffected siblings (n = 2271), compared to controls (n = 3301). An abbreviated WAIS-III measured verbal
knowledge, working memory, visuospatial processing, processing speed, and IQ. Patients showed medium to large deficits
across all functions (ES range = –0.45 to –0.73, p < 0.001), while siblings showed small deficits on IQ, verbal knowledge,
and working memory (ES = –0.14 to –0.33, p < 0.001). Magnitude of impairment was not associated with participant age,
such that the size of impairment in older and younger patients did not significantly differ. However, first-episode patients
performed worse than prodromal patients (ES range = –0.88 to –0.60, p < 0.001). Adjusting for cannabis use, symptom
severity, and global functioning attenuated impairments in siblings, while deficits in patients remained statistically
significant, albeit reduced by half (ES range = –0.13 to –0.38, p < 0.01). Antipsychotic medication also accounted for around
half of the impairment in patients (ES range = –0.21 to –0.43, p < 0.01). Deficits in verbal knowledge, and working memory
may specifically index familial, i.e., shared genetic and/or shared environmental, liability for psychotic disorders.
Nevertheless, potentially modifiable illness-related factors account for a significant portion of the cognitive impairment in
psychotic disorders.
These authors contributed equally: Eva Velthorst, Josephine Mollon
Members of the EU-GEI High Risk Study are listed below
Acknowledgements.
Supplementary information The online version of this article (https://
doi.org/10.1038/s41380-020-00969-z) contains supplementary
material, which is available to authorized users.
* Eva Velthorst
eva.velthorst@mssm.edu
Extended author information available on the last page of the article
E. Velthorst et al.
Introduction
Cognitive impairment is a common feature of schizophrenia
and related psychotic disorders. Some even argue that schizophrenia should be conceptualized as a cognitive rather than
psychotic illness, with cognitive dysfunction representing the
core component of the disorder [1, 2]. Indeed, the DSM-V
emphasizes the importance of assessing cognitive functioning
alongside the five symptom domains (delusions, hallucinations, disorganized speech, disorganized, behavior, negative
symptoms) [3], and in ICD-11, cognitive symptoms are listed
alongside positive, negative, depressive, manic, and psychomotor symptoms [4]. However, despite more than a century
of research on cognitive functioning in schizophrenia-related
disorders, important knowledge gaps remain.
First, the profile of cognitive impairment across the lifespan remains poorly characterized, and its relationship with
illness stages is unclear. Evidence suggests that patients with
schizophrenia-related disorders experience some degree of
cognitive decline over their lifetime, with the largest decline
occurring during the years prior and up to the first few years
after onset [5]. After illness onset, both cross-sectional [6] and
longitudinal [7] evidence suggests at least some stabilization
of impairment. However, there is also evidence for decline
after onset [8], a second ‘peak’ in decline during later, chronic
illness stages [9], and increased risk of dementia in very-late
onset schizophrenia [10]. Efforts to examine the profile of
specific cognitive functions across adulthood have also yielded mixed findings [6, 8]. Delineating the profile of these
functions across adulthood and illness stages may reveal critical functions and periods for detection and intervention.
Second, cognitive decline has not been fully considered as
an age-associated process, rather than in relation to stage of
illness (i.e., premorbid, first-episode, chronic) [5]. Similarly,
most studies have examined early [7] or late adulthood [9],
without being able to trace cognitive functioning across the
entirety of adulthood. While evidence suggests that cognitive
decline during the first two decades of life reflects a failure to
keep up with developmental norms rather than loss of cognitive capacity [11, 12], studies have not yet delineated the
nature of age-associated processes throughout adulthood. The
importance of considering cognitive functioning beyond
adolescence is highlighted by the fact that brain and cognitive
development continue well into the third decade of life [13].
Third, studies have yet to examine the full age-associated
profile of familial deficits. Substantial evidence suggests
that relatives of patients with schizophrenia-related disorders also show some degree of cognitive impairment
[14, 15], at least in part due to shared heritable genetic
mechanisms. The genetic underpinnings of cognitive
impairments in schizophrenia-related disorders have been
demonstrated by studies showing overlap between schizophrenia polygenic risk scores (PRS) and cognitive
performance [16], as well as educational attainment [17].
However, despite continued evidence for familial cognitive
impairments, it remains unclear whether siblings show
greater impairments in certain domains and whether the
age-associated pattern of cognitive impairments resembles
that of patients. A detailed evaluation of the familiality of
cognitive deficits across adulthood and cognitive domains
may provide important additional etiological clues about the
genetic and neurobiological underpinnings of cognitive
impairments in schizophrenia-related disorders.
Lastly, it remains unknown whether illness-related factors
such as symptom severity, global functioning, and antipsychotic medication influence cognitive impairments differentially throughout adulthood. The age-associated influence
of cannabis use on cognitive impairments is similarly unclear,
despite the role cannabis may play in the emergence of psychotic symptoms [18]. The potentially moderating effect of
sex on age-associated cognitive processes in psychotic disorders also remains largely unexplored. Examining these
factors across adulthood may advance understanding of the
etiology of cognitive impairment, as well as its clinical
significance.
Using the largest sample of patients with schizophreniarelated disorders, non-psychotic siblings, and controls to date,
we examined cognitive impairments across adulthood. We
used cross-sectional data on general and specific functions
from 8,455 individuals aged 18 to 65 from the Genetic
Risk and Outcome of Psychosis (GROUP) and EUropean
network of national schizophrenia networks studying GeneEnvironment Interactions (EU-GEI) studies, which comprise
prodromal (i.e., converted to a schizophrenia-related disorder
during the study), first-episode and established illness stages.
We examined whether: (1) cognitive impairments in patients
differ by age category (i.e., very early-, early- and midadulthood) and/or stage of illness (i.e., prodromal stage, firstepisode, established stage), (2) siblings of these patients show
a similar pattern of impairment, and (3) this impairment is
influenced by socioeconomic status, education, sex, symptom
severity, global functioning, antipsychotic medication, and
cannabis use.
Methods
Sample
Data were collected in 30 centers across 13 countries (UK,
Netherlands, Spain, France, Italy, Serbia, Turkey, Austria,
Switzerland, Germany, Australia, Denmark, Brazil), and were
part of the baseline assessment for the EU-GEI study, which
ran from May 1st 2010 to April 30th 2015 [19, 20], or the
GROUP study, which ran from April 2004 to December 2013
[21]. Ethical approval was granted in each center and all
Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders. . .
participants provided written informed consent. Of the combined dataset of 10,136 individuals, 685 (21.6%) patients, 259
(11.0%) siblings and 334 (10.0%) controls did not complete
cognitive testing, leaving a total of 8858 individuals (3341
controls, 2347 siblings, 3,170 patients). Patients were either in
the prodromal (i.e., had converted to a schizophrenia-related
disorder during the study period), first-episode or established
stage of illness, and were excluded if an organic cause was the
primary reason for their psychotic symptoms. Control participants were excluded if they had a past or current diagnosis
of any schizophrenia-related disorder. All participants had to
have adequate language skills local to each center in order to
undergo cognitive testing. Other exclusion and inclusion criteria for individual studies/work packages covering the different illness stages are described in the supplement.
Measures
training (κ = 0.7). Illness duration and current antipsychotic
medication use (yes/no) were assessed using the abbreviated
Nottingham Onset Schedule (NOS) [29]. Symptom severity
and general functioning were measured using the Global
Assessment of Functioning (GAF) symptom and disability
scales [30], respectively.
Statistical analyses
Group differences in sample characteristics were examined
using χ2, t- and Mann–Whitney-U-tests. Raw scores on the
digit symbol coding, block design, information and arithmetic subtests, and the sum of these subtests (i.e., raw IQ)
were z transformed. Thus, β values throughout represent
standardized effect sizes (ES), with values 0.2, 0.5, and 0.8
indicating small, medium, and large ESs, respectively.
These z scores were used in all statistical analyses, and are
plotted by age separately for each country in sFigs. 1–5.
Cognition
Age-associated group differences in cognitive functioning
An abbreviated WAIS-III [22], comprising the information,
arithmetic, block design, and digit symbol coding subtests,
was used to measure performance in the domains of verbal
knowledge, working memory visuospatial processing, and
processing speed, respectively. Each WAIS subtest taps into
many different abilities and the domains mentioned herein
are simplified. In GROUP, all items of each subtest were
administered. In EU-GEI, the digit symbol coding was
administered for the standard time, along with every second
item of the block design and arithmetic subtests, and every
third item of the information subtest [23]. Raw scores were
then multiplied by two (arithmetic and block design) or
three (information). This abbreviated WAIS-III version was
developed for EU-GEI and provides a reliable approximation of IQ and the four subtests [23].
Multilevel linear models (MLMs) were fitted to account for the
hierarchical structure of the data (i.e., with random intercepts
for country, center, and family). Based on age distributions
(sFig. 6) and nonlinear relationships between age and cognitive
functioning (Fig. 1), we categorized individuals into approximately equal-sized age groups: 18–25, 26–39, and 40–65
years, representing very early-, early- and mid-adulthood,
respectively (Table 1). Effects of interest were group main
effects and the interaction between group and age category. A
statistically significant group main effect would indicate a
difference in cognitive performance between patients and/or
siblings compared to controls. A statistically significant groupby-age interaction would indicate that group differences in
cognitive performance differ by participants’ age. Sex and
ethnicity were entered as covariates in all models.
Sociodemographic characteristics
Illness stage and duration
Age, sex, ethnicity, years of education, and parental
socioeconomic status (SES) were obtained (Table 1). In
EU-GEI, parental SES (i.e., occupation level) was obtained
using an amended version of the Medical Research Council
Socioeconomic Schedule (MRC SDS) [24], and in GROUP
using a comparable scale. Current cannabis use was ascertained in GROUP using the Composite International Diagnostic Interview (CIDI) [25] and in EUGEI using the
Cannabis Experiences Questionnaire (CEQ) [26].
The effect of illness stage was examined using MLMs as
described above, but with prodromal patients set as the
reference. Illness stage was based on study (i.e., prodrome
study = prodromal stage, first-episode study = first-episode,
course studies = established stage), except for individuals in
the course studies with an illness duration of less than 2
years (n = 314), who were considered first-episode. Illness
duration (measured in years from illness onset) was entered
into MLMs as a continuous effect of interest.
Clinical characteristics
Sociodemographic and illness-related factors
Diagnoses were obtained using the Operational Criteria
Checklist algorithm (OPCRIT) [27]. OPCRIT shows high
interrater reliability generally [28] and in our study, after
We entered sociodemographic and illness-related factors
(current cannabis use; symptom severity i.e., GAF
E. Velthorst et al.
Table 1 Sample characteristics.
Prodromea
N = 56
First-episodeb
N = 865
Established-stagec
N = 1962
Siblingsd
N = 2271
Controlse
N = 3,301
Group differences
n/mean
%/SD
n/mean
%/SD
n/mean
%/SD
n/mean
%/SD
n/mean
%/SD
32
–
22.80
–
57.1
–
4.33
–
530
–
30.72
–
61.3
–
10.46
–
1406
–
30.46
–
71.7
–
8.57
–
996
1
31.60
3
43.7
0.0
9.14
0.0
1609
–
34.23
2
48.7
–
11.68
0.0
a≠c,d; b≠c,d,e;
c≠d,e; d≠e
46
10
–
36
–
–
82.1
17.9
–
64.3
–
–
350
346
169
556
–
0.67
40.5
40.0
19.5
64.3
–
2.86
660
953
349
1721
27
6.27
33.6
48.6
17.9
88.9
1.4
6.02
701
1102
465
2036
6
–
30.9
48.6
20.5
89.9
0.3
–
921
1327
1051
2953
12
–
27.9
40.2
31.9
89.78
0.4
–
a≠b,c,d.e; b≠c,d,e;
c≠d,e; d≠e
–
9
20
–
25.0
35.7
298
816
18
34.5
96.3
2.1
485
1745
99
24.72
93.7
5.0
–
–
–
–
–
–
–
–
–
–
–
–
16
17
9
3
11
35.6
37.8
20.0
6.7
18.3
193
181
369
24
98
25.2
23.6
48.1
3.1
11.3
52
64
97
1
1748a
24.3
29.9
45.3
0.5
89.1a
59
77
90
1
2044a
26.0
33.9
39.7
0.4
90.0a
412
419
625
11
1834a
28.1
28.6
42.6
0.8
55.6a
a≠b,c,d,e; b≠d,e
22
5
3
5
2
–
–
3
5
7
–
4
–
14.36
9
15
2
51.65
4
52.14
–
39.3
8.9
5.4
8.9
3.6
–
–
5.4
8.9
12.5
17.9
20.4
–
–
21.4
–
–
–
–
10.1
18.7
–
11.6
4.22
2.1
22.1
1.0
17.50
4.4
16.53
4.3
–
998
–
–
385
528
51
–
–
–
–
–
–
12.14
98
205
566
54.60
139
54.32
143
–
50.9
–
–
19.6
26.9
2.6
–
–
–
–
–
–
3.98
5.0
14.7
28.8
16.54
7.1
16.82
7.3
5
1012
–
–
538
565
50
–
–
6
88
–
7
13.33
62
203
642
82.46
1097
84.91
1037
0.2
44.6
–
–
23.7
24.9
2.2
–
–
0.3
3.9
–
0.3
4.30
2.7
12.5
28.3
12.15
46.8
11.34
45.7
324
755
–
–
637
949
36
15
–
144
280
–
161
13.60
44
304
414
85.31
609
86.60
608
9.8
22.9
–
–
19.3
28.8
1.1
0.5
–
4.4
8.5
–
4.9
4.25
1.3
10.5
12.5
9.90
18.4
9.10
18.4
–
3.19
13.8
27.8
3.3
8.25
6.2
10.27
–
155
176
–
–
185
–
–
–
–
87
162
–
100
13.10
18
189
9
47.61
38
51.82
37
97.32
14.64
84.86
18.06
88.74
16.93
97.19
16.60
98.88
18.06
Information
Arithmetic
10.50
9.67
3.39
3.35
8.77
7.70
3.80
3.34
9.56
8.84
3.67
3.23
9.69
9.82
3.52
3.25
10.19
10.08
3.55
3.19
Block design
9.64
3.27
7.82
3.64
8.72
3.36
9.89
3.06
9.84
3.29
Symbol coding
8.70
2.76
6.68
2.91
5.99
3.43
9.04
3.66
9.10
4.06
a≠b,c; b≠c,d,e;
c≠d,e; d≠e
a≠b; b≠c,d,e; c≠e; d≠e
a≠b; b≠c,d,e;
c≠d,e; d≠e
a≠b; b≠c,d,e;
c≠d,e; d≠e
a≠b,c; b≠c,d,e; c≠d,e
Male
Missing
Age
Missing
Age category
18–25
26–39
40–65
White ethnicity
Missing
Illness duration in
years
Missing
Antipsychotics
Missing
Paternal SES
Higher
Intermediate
Lower
Unemployed
Missing
Country
UK
Netherlands
Austria
Switzerland
Spain
Turkey
Serbia
Australia
Germany
France
Brazil
Denmark
Italy
Years of education
Missing
Current cannabis use
Missing
GAF symptoms
Missing
GAF disability
Missing
Scaled cognition scores
IQ
a
7.1
Missingness due to comparable measures not being available in the GROUP study.
≠Significantly different at p < 0.05.
a≠b,c,d,e; b≠d,e; c≠d,
e; d≠e
a≠c,d,e; b≠c,d,e
b≠c
a≠b,c; b≠c
a≠c,d,e; b≠c,d,e; c≠d
a≠c,d,e; b≠c,d,e;
c≠e; d≠e
a≠d,e; b≠c,d,e;
c≠d,e; d≠e
a≠d,e; b≠c,d,e;
c≠d,e; d≠e
Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders. . .
IQ
1.0
0.5
z score
0.0
Controls
Siblings
Patients
-0.5
-1.0
-1.5
-2.0
20 25 30 35 40 45 50 55 60 65
Age
Arithmetic
1.0
0.5
0.5
0.0
0.0
Controls
Siblings
Patients
-0.5
z score
z score
Information
1.0
-1.0
-1.0
-1.5
-1.5
-2.0
-2.0
20 25 30 35 40 45 50 55 60 65
Age
20 25 30 35 40 45 50 55 60 65
Age
Block design
Digit symbol coding
1.0
1.0
0.5
0.5
0.0
0.0
Controls
Siblings
Patients
-0.5
z score
z score
Controls
Siblings
Patients
-0.5
-1.0
-1.0
-1.5
-1.5
-2.0
Controls
Siblings
Patients
-0.5
-2.0
20 25 30 35 40 45 50 55 60 65
Age
20 25 30 35 40 45 50 55 60 65
Age
Fig. 1 Loess curves of z scores against age for each groups. Lines represent the cognitive performance Z-scores (Y-axis) for controls (red),
siblings (green) and patients (blue) by age (X-axis).
symptoms; global functioning i.e., GAF disability; illness
duration; parental SES; years of education; antipsychotic
medication) as covariates into separate MLMs to examine
whether each of these factors influenced group and groupby-age effects.
Sex-related differences
We fitted MLMs separately in males and females to
examine potential sex differences in group and group-byage effects. In order to formally test for sex-related
E. Velthorst et al.
differences, we also entered sex-by-group, and three-way
interactions between sex, group, and age into MLMs on the
whole sample.
Sensitivity analyses
Sensitivity analyses were conducted to determine whether
cognitive patterns were similar in patients with non-affective
and affective psychosis. To rule out any potential bias due to
the inclusion of patients without a participating sibling (37.4%
of sample), we repeated the main analyses including only
patients with a participating sibling. We also analyzed controls and siblings with high GAF disability scores (80+,
controls: n = 2193; siblings: n = 834) and low GAF disability
scores (<80, controls: n = 400; siblings: n = 405) separately
to examine potential bias from missing GAF data.
An adjusted p-value threshold of 0.005 (0.05 ÷ 10
(5 cognitive subtests × 2 statistical models for (1) main
effects and (2) interaction effects)) was used in all models to
account for multiple comparisons. Statistical analyses were
performed in Stata 15.1 [31]. The R [32] package ggplot2
[33] was used to create graphics.
Results
Sample characteristics
Table 1 shows sample characteristics. The small number of
participants below the age of 18 were excluded (n = 179).
Thus, the final sample comprised 2883 patients, 2271 siblings, and 3301 controls. Of this sample, 1805 (62.6%)
patients had at least one participating sibling (range = 1–5;
median = 1).
Older participants showed lower scores than
younger participants
Across all groups, IQ (β = –0.42, z = –12.01, SE = 0.04,
p < 0.001), block design (β = –0.45, z = –11.39, SE = 0.04,
p < 0.001), and digit symbol coding (β = –0.42, z = –12.15,
SE = 0.04, p < 0.001) was significantly associated with
participant age, such that participants in mid-adulthood
performed worse than participants in very-early-adulthood
(Fig. 2, Table 2).
Patients showed substantial cognitive impairments
that were not associated with participant age
Patients showed medium to large deficits across all cognitive measures (Fig. 2, Table 2). Large deficits were seen
on IQ (β = –0.73, z = –20.39, SE = 0.04, p < 0.001),
and digit symbol coding (β = –0.71, z = –20.30, SE = 0.03,
p < 0.001). Medium deficits were observed on information
(β = –0.45, z = –11.05, SE = 0.04, p < 0.001), arithmetic
(β = –0.66, z = –15.87, SE = 0.04, p < 0.001), and block
design (β = –0.45, z = –11.05, SE = 0.04, p < 0.001). No
group-by-age interactions reached statistical significance,
suggesting no differential association between cognitive
performance and participant age in patients and controls.
Namely, older participants scored worse than younger participants in both groups, and the magnitude of difference
between older and younger participants was not significantly different between groups (Table 2).
First-episode patients performed worse than
patients in other illness-stages
First-episode patients performed worse than prodromal
patients on IQ (β = –0.88, z = –4.75, SE = 0.19, p < 0.001),
information (β = –0.60, z = –3.06, SE = 0.19, p = 0.002),
arithmetic (β = –0.61, z = –3.11, SE = 0.20, p = 0.002),
block design (β = –0.82, z = –4.07, SE = 0.20, p < 0.001),
and slightly worse than established stage patients on
information (β = –0.16, z = –3.72, SE = 0.04, p < 0.001).
Established stage patients performed worse than prodromal
patients on IQ (β = –0.80, z = –4.26, SE = 0.19, p < 0.001),
arithmetic (β = –0.58, z = –2.89, SE = 0.20, p = 0.004),
block design (β = –0.70, z = –3.42, SE = 0.20, p = 0.001),
and digit symbol coding (β = –0.66, z = 3.65, SE = 0.18,
p < 0.001). All differences remained after adjusting for age.
Illness duration showed no statistically significant effects on
cognition.
Siblings showed small cognitive impairments that
were smaller in older than younger participants
Compared to controls, siblings showed small deficits on IQ
(β = –0.14, z = –3.65, SE = 0.04, p < 0.001), information
(β = –0.33, z = –7.64, SE = 0.04, p < 0.001) and arithmetic
(β = –0.23, z = –4.97, SE = 0.05, p < 0.001) (Fig. 2,
Table 2). These deficits were smaller in mid-adulthood than
in early-adulthood, reflected by significant group-by-age
interactions on IQ (β = 0.16, z = 2.88, SE = 0.06, p =
0.004), information (β = 0.22, z = 3.47, SE = 0.06, p =
0.001) and block design (β = 0.20, z = 3.15, SE = 0.06,
p = 0.002) (Table 2). Thus, while older participants scored
worse than younger participants in both groups, the magnitude of difference between older and younger participants
was smaller in siblings than controls.
Sociodemographic and illness-related factors
influenced cognitive impairments
Figure 3 shows differences in effect sizes of group main
effects for models adjusting for each covariate, compared to
Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders. . .
IQ
Fig. 2 Cognitive z scores at
each age category by group.
Cognitive scores for controls
aged 18–25 set to 0 i.e., as
reference category.
0.0
-0.2
z score
-0.4
Controls
Siblings
Patients
-0.6
-0.8
-1.0
-1.2
18-25
26-39
Age category
40-65
Arithmetic
0.0
0.0
-0.2
-0.2
-0.4
-0.4
Controls
Siblings
Patients
-0.6
z score
z score
Information
-0.8
-0.8
-1.0
-1.0
-1.2
-1.2
18-25
26-39
Age category
40-65
18-25
26-39
Age category
40-65
Digit symbol coding
0.0
0.0
-0.2
-0.2
-0.4
-0.4
Controls
Siblings
Patients
-0.6
z score
z score
Block design
-0.8
-1.0
-1.0
-1.2
-1.2
26-39
Age category
the unadjusted model. Adjusting for parental SES statistically attenuated deficits in verbal knowledge, and working
memory in siblings, but effect sizes remained small
(sTable 1, sFig. 7). Adjusting for current cannabis use
(sTables 2, sFig. 8) and years of education (sTables 3,
sFig. 9) attenuated the small IQ deficit in siblings. Adjusting
for symptom severity (GAF symptoms) (sTable 4, sFig. 10)
and global functioning (GAF disability) (sTable 5, sFig. 11)
attenuated the IQ and arithmetic deficits in siblings, and the
40-65
Controls
Siblings
Patients
-0.6
-0.8
18-25
Controls
Siblings
Patients
-0.6
18-25
26-39
Age category
40-65
block design impairment in patients. Information, arithmetic, and symbol coding deficits in patients remained
statistically significant, but were reduced by more than half
when adjusting for these factors (sTables 4 and 5). Interestingly, when entering both global functioning and symptom severity into the same model, only functioning
remained statistically associated with cognition (z = 9.84,
SE = 0.001, p < 0.001), while symptoms were not (z = 1.59,
SE = 0.001, p = 0.11). This finding suggests that the
–0.35
Bolded estimates signify a statistical significant difference between the cognitive score of patients or siblings with the control group (p < 0.005).
Since cognitive test scores were z transformed, β coefficients correspond to standardized ESs (values 0.2, 0.5 and 0.8 indicate small, medium and large ESs, respectively).
–0.37
0.47
0.06
0.05
0.73
0.61
0.04
0.03
–0.04
–0.01
0.63
0.99
0.04
0.05
0.48
–0.02
0
0.02
0.35
<0.001
0.03
0.04
–0.94
–20.30
–0.71
–0.04
0.03
Patients
0.32
<0.001
0.03
–0.99
–0.42
40–65
26–39
–0.03
–12.15
Siblings
–
–
–
–
–
–
Symbol coding
18–25
–
–
Controls
–
0.01
0.08
0.05
<0.001
0.04
0.04
–1.95
–0.45
–11.05
–0.09
Patients
0.14
<0.001
0.04
–1.45
–11.39
–0.45
40–65
26–39
–0.06
0.04
Siblings
–
–
–
–
–
–
Block design
18–25
–
–
Controls
–
0.05
0.06
<0.001
<0.001
0.04
0.05
–4.97
–15.87
–0.66
–0.23
0.02
Patients
0.68
0.04
0.41
–2.32
0.02
40–65
26–39
–0.09
0.04
Siblings
–
–
–
–
Arithmetic
18–25
–
–
–
–
Controls
–
0.06
0.12
<0.001
<0.001
0.04
0.04
–7.64
–11.24
–0.46
–0.33
Patients
0.04
0.04
0.43
0.77
0.03
26–39
40–65
0.02
2.37
0.09
Information
18–25
–
–
–
–
Siblings
–
–
–
–
Controls
–
0.03
<0.001
0.04
–0.73
<0.001
–12.01
40–65
–0.42
0.04
Patients
–20.39
–
0.08
<0.001
–
–
0.04
–3.65
–
–
–0.14
Siblings
Controls
–
0.46
–
0.03
–
–0.73
–
–0.02
26–39
18–25
IQ
association between functioning and cognition may account
for most of the association between symptoms and cognition. Finally, adjusting for antipsychotic medication attenuated the information and block design impairments in
patients, and reduced the magnitude of deficits in IQ,
arithmetic, and digit symbol coding by about half (sTable 6,
sFig. 12). sTable 7 shows correlations between sociodemographic and illness-related factors and all cognitive
measures.
0.54
–0.39
–0.38
–
–
–
–
–0.03
–
–
–
–0.28
0.06
0.27
0.06
1.11
0.07
0.11
0.05
0.16
0.82
0.05
0.05
1.41
0.22
0.20
3.15
0.002
–0.06
–0.39
–
–
–
–
0.14
–
–
–
–0.13
0.06
0.03
0.07
2.24
0.14
0.11
0.14
0.03
0.07
0.05
0.06
2.24
1.80
0.11
1.65
0.10
0
–0.11
–
–
–
–
0.02
–
–
–
0.04
0.06
0.05
0.06
1.97
0.12
0.15
0.21
0.03
0.21
0.05
0.05
2.17
1.26
0.22
3.47
0.001
–0.34
–0.06
–
–
–
–
0.09
–
–
–
–0.32
0.05
0.56
0.05
0.57
0
0.08
1.56
0.12
–0.40
–
0.004
–
0.06
–
–
–0.03
0.06
0.09
–
–
0.05
1.72
–
0.16
2.88
p
SE
z
β
p
SE
z
Group-by-age interactionVery-early- to early-adulthood
β
p
SE
z
β
Group effect
Group
p
SE
z
β
Age
Age effect
Measure
Table 2 Age, group and group-by-interaction effects on cognitive measures, adjusting for sex and ethnicity.
ΔES
Group-by-age interactionEarly- to mid-adulthood
ΔES
E. Velthorst et al.
Cognitive impairments were comparable in male
and female patients but not male and female
siblings
Compared to controls, both male and female patients
showed medium to large impairments across all cognitive
measures (sTables 8 and 9). Accordingly, sex-by-group
interactions did not reveal any sex-related differences in
patients on any cognitive measure, such that cognitive
impairments were comparable in male and female patients.
On the other hand, male siblings showed a smaller deficit on
information (β = –0.21, z = –3.34, SE = 0.06, p = 0.001),
than female siblings (β = –0.40, z = –6.72, SE = 0.06, p <
0.001), and the deficit on arithmetic did not reach significance in male siblings (β = –0.12, z = –1.83, SE = 0.07,
p = 0.07), but did in female siblings (β = –0.30, z = –4.94,
SE = 0.06, p < 0.001) (sTables 8 and 9, sFigs. 13 and 14).
Accordingly, significant sex-by-group interactions on
information (β = –0.11, z = –2.46, SE = 0.05, p = 0.014)
and arithmetic (β = –0.13, z = –0.05, SE = 2.66, p =
0.008), confirmed that female siblings showed greater deficits on these domains than male siblings.
Group-by-age interactions no longer reached significance
in male siblings, but female siblings showed a significant
group-by-age interaction on information between early- and
mid-adulthood (β = 0.27, z = 3.25, SE = 0.08, p = 0.001),
suggesting a differential association between cognitive
performance and participant age in female siblings and
controls (sTables 8 and 9). Namely, while older participants
scored worse than younger participants across groups,
the magnitude of difference between older and younger
participants was smaller in female siblings than controls.
However, none of the sex-by-group-by-age interactions
reached statistical significance, suggesting negligible sexrelated differences in age-associated effects on cognitive
functioning.
Sensitivity analyses
Sensitivity analyses comparing patients with non-affective
and affective psychosis, patients with and without participating siblings, and participants with high and low GAF
scores revealed similar patterns overall (sResults).
Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders. . .
Patients
Siblings
0.6
Difference in effect size from unadjusted model
Fig. 3 Difference in effect size
of group effect in models
adjusting for each covariate
compared to main model.
Positive differences in effect size
indicate reduced difference
between controls and patients/
siblings and negative differences
in effect size indicate increased
difference between controls and
patients/siblings.
0.5
0.4
0.3
Covariate
Paternal SES
Cannabis use
Education
GAF symptoms
GAF functioning
Antipsychotics
0.2
0.1
0.0
-0.1
-0.2
-0.3
IQ
Inf
orm
on
a ti
Ar
m
ith
n
g
n
n
g
tic
IQ
tio
sig
sig
din
din
me
co
de
de
co
ma
rith
ol
ol
fo r
ck
ck
A
b
b
n
o
o
l
l
I
m
m
B
B
Sy
Sy
Cognitive measure
et i
c
Discussion
In this large, cross-sectional patient-sibling-control study,
patients with psychotic disorders showed large, widespread
cognitive impairments, which were not associated with
participant age. However, first-episode patients showed
larger deficits than prodromal patients, and a slightly larger
verbal knowledge deficit compared to established stage
patients. Siblings showed small deficits on IQ, and measures of verbal knowledge and working memory, which
were attenuated when adjusting for cannabis use, symptom
severity, global functioning, and education. These findings
add to current knowledge in several important ways.
First, effects of participant age on the magnitude of
cognitive impairments were minimal. Examining cognitive
raw scores throughout adulthood revealed that older patients
showed lower scores than younger patients, but also that the
same was true of controls, such that the magnitude of
impairment remained stable. However, magnitude of
impairment did differ by illness stage, with first-episode
patients showing much larger deficits than prodromal
patients. In line with previous evidence [34], impairments in
the oldest siblings were smaller than impairments in the
youngest siblings, which may be because older siblings
have passed the critical period for psychosis-onset, while
younger siblings have not and may still be at risk for psychotic disorders. Alternatively, controls may experience
greater age-associated cognitive decline later in adulthood,
while siblings and patients, who already experienced
decline earlier in adulthood, may show relative stabilization
or even normalization [6]. Our results should also be considered in the context of the well-documented Flynn effect
[35], whereby cognitive performance and IQ in any fixed
age group improves over time due to improvements in
education, nutrition, etc. Thus, while our finding of lower
cognitive scores in older participants compared to younger
participants may reflect age-associated cognitive decline
[36, 37], the Flynn effect may also account for this finding.
Conversely, recent data suggest a reversal of the Flynn
effect [38–40], which may partly explain our finding of
smaller impairments in older siblings compared to younger
siblings. Moreover, while we made considerable efforts to
recruit a well-matched representative sample using quota
sampling methods, we cannot rule out selection bias. For
example, participation in research studies is associated with
better cognitive functioning and this bias may be more
pronounced in later adulthood. Similarly, since lower IQ is
associated with earlier mortality [41], older individuals with
more pronounced cognitive impairment may be less likely
to participate. Future longitudinal studies that are able to
prospectively follow individuals throughout adulthood are
needed to determine the profile and underlying mechanisms
of age-associated cognitive processes in psychotic disorders. Overall, our findings support previous evidence that
most of the cognitive deficit associated with psychotic
disorders is already apparent at illness onset [7].
Second, including a large sample of siblings with similar
genetic and environmental predispositions as patients, but
without the potentially confounding effects of illnessrelated factors, provides important insights into the familiality of cognitive impairments [14]. Specifically, while
patients showed medium to large deficits across all measures, siblings showed small deficits on IQ, verbal knowledge, and working memory, but not on processing speed
and visuospatial processing. This latter finding contrasts
with a meta-analytic finding of large processing speed
deficits in first-degree relatives [42], likely because most
studies in this meta-analysis combined data from parents
and siblings, while we only examined siblings, who are
younger. Nevertheless, our findings suggest that verbal
E. Velthorst et al.
knowledge and working memory deficits may specifically
index familial, i.e., shared genetic and/or environmental,
liability for psychotic disorders. Accordingly, a recent metaanalysis of cognition in first-degree relatives of patients
with schizophrenia also reported the largest deficits in IQ
and verbal measures [15]. The notion of verbal impairments
as a familial marker for psychotic illness is in line with
evidence that verbal deficits emerge early [11, 12]. Nonverbal impairments, on the other hand, emerge over time
[12], increase throughout the early illness stage [11], but
remain stable thereafter [8]. Thus, shared genetic and/or
environmental factors may lead to deficits in verbal abilities
in individuals at familial risk for psychosis, while additional
risk factors, possibly interacting with these verbal deficits,
may lead to emerging nonverbal deficits and psychotic illness. It is important to note that we examined only two
cognitive tests requiring verbal skills, and shared genetic
liability may depend on the subtest measured. For example,
genomic loci that jointly influence schizophrenia and
verbal-numerical reasoning have been identified [43], but a
recent study showed no association between schizophrenia
PRSs and a verbal reading test [44].
Third, adjusting for both symptom severity and global
functioning attenuated the IQ and working memory deficits
in siblings, and reduced cognitive deficits in patients by
half. Yet our findings also suggest that the association
between symptoms and cognition is confounded by functioning. Thus, while the two GAF subscales are highly
correlated (r = 0.69) and adjusting for each subscale
reduced deficits by similar magnitudes, it may be important
to disentangle the effects of these factors. These findings are
line with evidence of the significant impact of cognition on
functional outcomes [45], as well as the lack of a strong
association between cognition and symptom severity [46].
Interestingly, siblings outperformed controls in visuospatial
ability and processing speed after adjustment for symptoms
and functioning, suggesting a potentially protective
mechanism. Deficits in working memory, visuospatial, and
processing speed abilities may therefore be ameliorated by
improving functioning levels. Impairments in both patients
and siblings were also reduced, albeit to a lesser extent,
when adjusting for education. Interestingly, this reduction
was slightly more pronounced on the verbal knowledge and
working memory tests, suggesting that these deficits may
partly reflect an impairment in the ability to learn in standard educational settings. While the relationship between
cognitive impairment and factors such as educational
attainment and functioning are difficult to discern due to
reverse causality, future studies that are able to disentangle
whether they act as mediators, moderators, or lie on the
causal pathway between cognition and psychosis will provide important insights. The finding that female siblings
showed larger deficits than male siblings is also intriguing,
and highlights the need for further examination of sexspecific genetic risk factors [47]. Finally, adjusting for
current cannabis use had a negligible impact on patient
impairments, but attenuated IQ deficits in siblings. These
findings are in line with evidence of a minimal association
between cannabis use and cognitive functioning in psychotic disorders [48], as well as more severe symptomatology in sibling cannabis users [49].
This study has some limitations. First, our findings require
replication in longitudinal samples since we used crosssectional data. We also cannot rule out age-associated effects
on cognition in early life or late adulthood since our youngest
and oldest participants were 18 and 65, respectively. Moreover, while the large age range is a strength, cohort effects
should be considered. Nevertheless, the current findings are in
line with longitudinal results from the same sample [50].
Second, one limitation inherent to large cohorts is the tradeoff
between breadth and depth. While we examined a number of
covariates, future studies that are able to examine antipsychotic dosage, type and adherence, comorbidities, such as
anxiety and depression, and positive and negative psychotic
symptoms are needed. Comorbidity is the rule rather than the
exception in psychotic disorders [51], making it difficult to
disentangle the effects of psychotic versus other psychiatric
symptoms. The reduction in power due to missing data when
adjusting for covariates also warrants consideration, and effect
sizes should be considered alongside statistical significance.
Third, while our sensitivity analyses eliminate certain sources
of bias, others cannot be ruled out. Individuals with better
functioning may be more likely to participate in research
studies, although the reverse is also possible. Fourth, our
findings regarding specific cognitive domains require replication using larger test batteries that are able to cover each
domain in greater detail. Relatedly, abbreviated tests, such as
those administered in EUGEI, may both over-estimate
(reduced fatigue) and underestimate (less attenuated learning) cognitive functioning, especially in individuals of low
ability [23]. However, our data show normal distribution of
IQ and subtest scaled scores across all groups (see sTable 10).
In conclusion, using a large, cross-sectional sample of
patients with psychotic disorders, their siblings and controls, we found that patients showed substantial and widespread cognitive impairments, while siblings showed
smaller verbal knowledge and working memory impairments. Moreover, effects of age and illness stage (beyond
the first episode) on these impairments were minimal, while
illness-related factors accounted for much of the impairment
in siblings, and around half of the patient deficit. Thus, our
findings suggest that most of the cognitive impairment
associated with psychotic disorders is already apparent at
illness onset, highlighting the importance of early cognitive
remediation intervention efforts. Therapeutic efforts targeting illness-related factors, such as symptoms and
Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders. . .
functioning, which account for a significant portion of the
cognitive impairment, could also have substantial benefits.
Finally, deficits in verbal knowledge and working memory
may specifically index familial liability and could be useful
targets for studies aimed at elucidating the heritable neurobiological mechanisms underlying psychotic disorders.
Acknowledgements The European Community’s Seventh Framework
Programme under grant agreement No. HEALTH-F2-2010-241909 (EUGEI). The Geestkracht programme of the Dutch Health Research Council
(Zon-Mw)(GROUP). Dr. Velthorst is supported by The Seaver Foundation. Dr. Pantelis was supported by a NHMRC Senior Principal Research
Fellowship (ID: 1105825), a NHMRC Program Grant (ID: 1150083). The
Melbourne arm of the study was supported by a grant from the Australian
National Health & Medical Research Council (NHMRC-EU grant ID:
567215). The French cohort was supported by the French Ministry grant
(PHRC ICAAR - AOM07-118). The Spanish sample was supported by
the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos
III (SAM16PE07CP1, PI16/02012, PI19/024), Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), Fundación Familia Alonso
and Fundación Alicia Koplowitz. The Brazilian sample was supported by
FAPESP-Brazil (grant 2012/05178-0). Additional support was provided
by a Medical Research Council Fellowship to Dr. Kempton (grant MR/
J008915/1). Dr. Kirkbride was supported by the National Institute for
Health Research University College London Hospital Biomedical
Research Centre. Dr. Nelson was supported by an NHMRC Senior
Research Fellowship (1137687). We would like to thank the EU-GEI
WP2 Group not mentioned in main author list: Kathryn Hubbard, Stephanie Beards, Simona A. Stilo, Pedro Cuadrado, José Juan Rodríguez
Solano, David Fraguas, Álvaro Andreu-Bernabeu, Gonzalo López, Bibiana Cabrera, Juan Nacher, Javier Costas, Mario Matteis [8], Marta
Rapado-Castro, Emiliano González, Covadonga M. Díaz-Caneja [8],
Emilio Sánchez, Manuel Durán-Cutilla, Nathalie Franke, Fabian Termorshuizen, Daniella van Dam, Elles Messchaart, Marion Leboyer [4],
Franck Schürhoff, Stéphane Jamain, Grégoire Baudin, Aziz Ferchiou,
Baptiste Pignon, Jean-Romain Richard, Thomas Charpeaud, Anne-Marie
Tronche, Flora Frijda, Giovanna Marrazzo, Crocettarachele Sartorio,
Fabio Seminerio, Camila Marcelino Loureiro, Rosana Shuhama, Mirella
Ruggeri, Chiara Bonetto, Doriana Cristofalo, Domenico Berardi, Marco
Seri, Elena Bonora, Anastasios Nougus, Giuseppe D’Andrea, Laura
Ferraro, Giada Tripoli, Ulrich Reininghaus, Enrique García Bernardo,
Laura Roldán, Esther Lorente-Rovira, Ma Soledad Olmeda, Daniele La
Barbera, Cristina M. Del-Ben, Lucia Sideli. Study funders contributed to
the salaries of the research workers employed, but did not participate in
the study design, data analyses, data interpretation, or writing of the
manuscript. All authors had full access to the study data and had final
responsibility for the decision to submit for publication.
EU-GEI High Risk Study Maria Calem5, Stefania Tognin5, Gemma
Modinos5, Sara Pisani5, Tamar C. Kraan3, Daniella S. van Dam3,
Nadine Burger53, G. Paul Amminger58, Athena Politis58, Joanne
Goodall58, Stefan Borgwardt77, Erich Studerus77, Ary Gadelha55, Elisa
Brietzke78, Graccielle Asevedo55, Elson Asevedo55, Andre Zugman55,
Tecelli Domínguez-Martínez79, Manel Monsonet80, Paula CristóbalNarváez80, Anna Racioppi56, Thomas R. Kwapil81, Mathilde Kazes61,
Claire Daban61, Julie Bourgin61, Olivier Gay61, Célia Mam-LamFook61, Dorte Nordholm82, Lasse Rander82, Kristine Krakauer82,
Louise Birkedal Glenthøj82, Birte Glenthøj83, Dominika Gebhard62,
Julia Arnhold84, Joachim Klosterkötter62, Iris Lasser63, Bernadette
Winklbaur63
77
University of Basel, Basel, Switzerland; 78Department of Psychiatry, Escola Paulista de Medicina, Universidade Federal de São
Paulo (UNIFESP), São Paulo, Brazil; 79CONACYT-Dirección de
Investigaciones Epidemiológicas y Psicosociales, Instituto Nacional de
Psiquiatría Ramón de la Fuente Muñiz, México, México; 80Departament de Psicologia Clínica i de la Salut (Universitat Autònoma de
Barcelona), Barcelona, Spain; 81Department of Psychology, University
of Illinois at Urbana-, Champaign, IL, USA; 82Mental Health Center
Copenhagen and Center for Clinical Intervention and Neuropsychiatric
Schizophrenia Research, CINS, Mental Health Center Glostrup,
Mental Health Services in the Capital Region of Copenhagen,
University of Copenhagen, Copenhagen, Denmark; 83Centre for
Neuropsychiatric Schizophrenia Research (CNSR) & Centre for
Clinical Intervention and Neuropsychiatric Schizophrenia Research
(CINS), Mental Health Centre Glostrup, University of Copenhagen,
Glostrup, Denmark; 84Psyberlin, Berlin, Germany
Compliance with ethical standards
Conflict of interest Dr. Arango. has been a consultant to or has
received honoraria or grants from Acadia, Angelini, Gedeon Richter,
Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier,
Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and
Takeda. Dr. Pantelis has received honoraria for talks at educational
meetings and has served on an advisory board for Lundbeck, Australia
Pty Ltd. Dr. Bernardo has been a consultant for, received grant/
research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Eli
Lilly, Ferrer, Forum Pharmaceuticals, Janssen-Cilag, Lundbeck,
Menarini, Otsuka, Takeda and Somatics. MO Krebs received financial
support from Janssen, Otsuka Lundbeck alliance, EIsai for educational
activities. All other authors report no financial relationships with
commercial interests.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
References
1. Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for
a change in focus. JAMA Psy. 2013;70:1107–12.
2. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia
is the core of the disorder. Critical Rev Neurobiol. 2000;14:1–21.
3. American Psychiatric Association. Diagnostic and statistical manual
of mental disorders (DSM-5®). Washington, D.C.: American
Psychiatric Association; 2013.
4. World Health Organization. International classification of diseases, 11th revision (ICD-11). ICD-11 is here Geneva: World
Health Organization; 2018.
5. Becker H, Nieman D, Wiltink S, Dingemans P, Van de Fliert J,
Velthorst E, et al. Neurocognitive functioning before and after the
first psychotic episode: does psychosis result in cognitive deterioration? Psych Med. 2010;40:1599–606.
6. Mollon J, Mathias SR, Knowles EE, Rodrigue A, Koenis MM,
Pearlson GD, et al. Cognitive impairment from early to middle
adulthood in patients with affective and nonaffective psychotic
disorders. Psychol Med. 2019;50:48–57.
7. Bozikas VP, Andreou C. Longitudinal studies of cognition in first
episode psychosis: a systematic review of the literature. Aust
NZealand J Psych. 2011;45:93–108.
8. Zanelli J, Mollon J, Sandin S, Morgan C, Dazzan P, Pilecka I,
et al. Cognitive change in schizophrenia and other psychoses in
the decade following the first episode. Am J Psychiatry. 2019;
176:811–9.
9. Harvey PD. What is the evidence for changes in cognition and
functioning over the lifespan in patients with schizophrenia?
J Clin Psychiatry. 2014;75:34–38.
E. Velthorst et al.
10. Kodesh A, Goldberg Y, Rotstein A, Weinstein G, Reichenberg A,
Sandin S, et al. Risk of dementia and death in very-late-onset
schizophrenia-like psychosis: a national cohort study. Schizophrenia
Res. 2020;223:220–6.
11. Mollon J, David AS, Zammit S, Lewis G, Reichenberg A. Course
of cognitive development from infancy to early adulthood in the
psychosis spectrum. JAMA Psychiatry. 2018;75:270–9.
12. Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS,
Murray RM, et al. Static and dynamic cognitive deficits in
childhood preceding adult schizophrenia: a 30-year study. Am J
Psyc. 2010;167:160–9.
13. Lebel C, Walker L, Leemans A, Phillips L, Beaulieu C. Microstructural maturation of the human brain from childhood to
adulthood. Neuroimage. 2008;40:1044–55.
14. Snitz BE, MacDonald III AW, Carter CS. Cognitive deficits in
unaffected first-degree relatives of schizophrenia patients: a metaanalytic review of putative endophenotypes. Schizophr Bull.
2005;32:179–94.
15. Agnew-Blais J, Seidman LJ. Neurocognition in youth and young
adults under age 30 at familial risk for schizophrenia: a quantitative and qualitative review. Cogn Neuropsychiatry. 2013;18:
44–82.
16. van Os J, van der Steen Y, Islam MA, Guloksuz S, Rutten BP,
Simons CJ, et al. Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion
regulation and attribution of salience. Psychol Med. 2017;47:
2421–37.
17. Sorensen HJ, Debost JC, Agerbo E, Benros ME, McGrath JJ,
Mortensen PB, et al. Polygenic risk scores, school achievement,
and risk for schizophrenia: a danish population-based study. Biol
Psychiatry. 2018;84:684–91.
18. Kuepper R, van Os J, Lieb R, Wittchen H-U, Höfler M, Henquet
C. Continued cannabis use and risk of incidence and persistence
of psychotic symptoms: 10 year follow-up cohort study. Bmj.
2011;342:d738.
19. EU-GEI. Identifying gene-environment interactions in schizophrenia:
contemporary challenges for integrated, large-scale investigations.
Schizophrenia Bulletin. 2014;40:729–36.
20. Gayer-Anderson C, Jongsma HE, Di Forti M, Quattrone D,
Velthorst E, de Haan L, et al. The EUropean Network of National
Schizophrenia networks studying gene–environment interactions
(EU-GEI): incidence and first-episode case–control programme.
Social Psych Psych Epidemiol. 2020:55:645–57.
21. Korver N, Quee PJ, Boos HB, Simons CJ, de Haan L, Investigators G. Genetic Risk and Outcome of Psychosis (GROUP), a
multi site longitudinal cohort study focused on gene–environment
interaction: objectives, sample characteristics, recruitment and
assessment methods. Int J Methods Psych Res. 2012;21:205–21.
22. Blyler CR, Gold JM, Iannone VN, Buchanan RW. Short form of
the WAIS-III for use with patients with schizophrenia. Schizophrenia Res. 2000;46:209–15.
23. Velthorst E, Levine SZ, Henquet C, de Haan L, van Os J,
Myin-Germeys I, et al. To cut a short test even shorter: reliability
and validity of a brief assessment of intellectual ability in schizophrenia—a control-case family study. Cog Neuropsych. 2013;
18:574–93.
24. Mallet J. MRC sociodemographic schedule. Section of Social
Psychiatry, Institute of Psychiatry; 1997.
25. WHO. Composite international diagnostic interview. Geneva,
Switzerland: World Health Organization; 1990.
26. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis.
Br J Psych. 2009;195:488–91.
27. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of
operational criteria in studies of psychotic illness: development
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
and reliability of the OPCRIT system. Arch Gen Psych. 1991;48:
764–70.
Craddock N, Asherson P, Owen MJ, Williams J, Mcguffin P,
Farmer AE. Concurrent validity of the OPCRIT diagnostic system: comparison of OPCRIT diagnoses with consensus bestestimate lifetime diagnoses. Br J Psych. 1996;169:58–63.
Singh SP, Cooper JE, Fisher HL, Tarrant CJ, Lloyd T, Banjo J,
et al. Determining the chronology and components of psychosis
onset: the Nottingham Onset Schedule (NOS). Schizophrenia Res.
2005;80:117–30.
Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental
health outcome scale: reliability and validity of the Global
Assessment of Functioning (GAF). Br J Psych. 1995;166:654–9.
StataCorp. Stata Statistical Software: Release 15. College Station,
TX: StataCorp; 2017. https://www.stata.com/features/documenta
tion/. Accessed on 1 March 2018.
R-Core-Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing;
2014. http://www.R-project.org.
Wickham H. ggplot2: Elegant graphics for data analysis. New
York: Springer-Verlag; 2016.
Zalesky A, Pantelis C, Cropley V, Fornito A, Cocchi L, McAdams
H, et al. Delayed development of brain connectivity in adolescents
with schizophrenia and their unaffected siblings. JAMA Psychiatry.
2015;72:900–8.
Flynn JR. What is intelligence?: Beyond the Flynn effect.
Cambridge, UK: Cambridge University Press; 2007.
Salthouse TA. When does age-related cognitive decline begin?
Neurobiol Aging. 2009;30:507–14.
Deary IJ, Corley J, Gow AJ, Harris SE, Houlihan LM, Marioni
RE, et al. Age-associated cognitive decline. Br Med Bull. 2009;
92:135–52.
Dutton E, van der Linden D, Lynn R. The negative Flynn Effect: a
systematic literature review. Intelligence. 2016;59:163–9.
Teasdale TW, Owen DR. A long-term rise and recent decline in
intelligence test performance: the Flynn Effect in reverse. Pers Ind
Diff. 2005;39:837–43.
Bratsberg B, Rogeberg O. Flynn effect and its reversal are both
environmentally caused. Proc Nat Acad Sci. 2018;115:6674–8.
Sachs GA, Carter R, Holtz LR, Smith F, Stump TE, Tu W, et al.
Cognitive impairment: an independent predictor of excess mortality: a cohort study. Ann Intern Med. 2011;155:300–8.
Dickinson D. Digit symbol coding and general cognitive ability in
schizophrenia: worth another look? Br J Psychiatry. 2008;193:
354–6.
Smeland OB, Frei O, Kauppi K, Hill WD, Li W, Wang Y, et al.
Identification of genetic loci jointly influencing schizophrenia risk
and the cognitive traits of verbal-numerical reasoning, reaction time,
and general cognitive function. JAMA Psychiatry. 2017;74:1065–75.
Shafee R, Nanda P, Padmanabhan JL, Tandon N, Alliey-Rodriguez
N, Kalapurakkel S, et al. Polygenic risk for schizophrenia and
measured domains of cognition in individuals with psychosis and
controls. Transl Psychiatry. 2018;8:78.
Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J,
Krabbendam L. The relationship between neurocognition and
social cognition with functional outcomes in schizophrenia: a
meta-analysis. Neurosci Biobehav Rev. 2011;35:573–88.
Gold JM. Cognitive deficits as treatment targets in schizophrenia.
Schizophr Res. 2004;72:21–28.
Goldstein JM, Cherkerzian S, Tsuang MT, Petryshen TL. Sex
differences in the genetic risk for schizophrenia: History of the
evidence for sex‐specific and sex‐dependent effects. Am J Med
Gen Part B: Neuropsych Genetics. 2013;162:698–710.
Loberg EM, Hugdahl K. Cannabis use and cognition in schizophrenia. Front Hum Neurosci. 2009;3:53.
Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders. . .
49. van Winkel R, Investigators G. Further evidence that cannabis
moderates familial correlation of psychosis-related experiences.
PLoS One. 2015;10:e0137625.
50. Van Haren NEM, Van Dam DS, Stellato RK. Genetic risk and
outcome of psychosis (group) investigators. Change in IQ in
schizophrenia patients and their siblings: a controlled longitudinal
study. Psychol Med. 2019;49:2573–81.
51. Knowles EEM, Mathias SR, Pearlson GD, Barrett J, Mollon J,
Denbow D, et al. Clinical correlates of subsyndromal depression
in African American individuals with psychosis: The relationship
with positive symptoms and comorbid substance dependence.
Schizophr Res. 2019;206:333–46.
Affiliations
Eva Velthorst 1,2,3 Josephine Mollon 4 Robin M. Murray 5 Lieuwe de Haan3,6 Inez Myin Germeys7
David C. Glahn4 Celso Arango8 Els van der Ven9,10 Marta Di Forti11,12 Miguel Bernardo13 Sinan Guloksuz10,14
Philippe Delespaul10,15 Gisela Mezquida13 Silvia Amoretti 13 Julio Bobes 16 Pilar A. Saiz16
María Paz García-Portilla16 José Luis Santos16,17,18 Estela Jiménez-López16,19 Julio Sanjuan20
Eduardo J. Aguilar20 Manuel Arrojo21 Angel Carracedo22,23 Gonzalo López16 Javier González-Peñas16
Mara Parellada8 Cem Atbaşoğlu 24 Meram Can Saka24 Alp Üçok25 Köksal Alptekin26,27 Berna Akdede26
Tolga Binbay26 Vesile Altınyazar28 Halis Ulaş26 Berna Yalınçetin27 Güvem Gümüş-Akay29,30
Burçin Cihan Beyaz31 Haldun Soygür32 Eylem Şahin Cankurtaran33 Semra Ulusoy Kaymak34 Nadja P. Maric35
Marina M. Mihaljevic35 Sanja Andric Petrovic36 Tijana Mirjanic37 Cristina Marta Del-Ben 38 Laura Ferraro5
Charlotte Gayer-Anderson39 Peter B. Jones 40 Hannah E. Jongsma40,41 James B. Kirkbride 41
Caterina La Cascia42 Antonio Lasalvia43 Sarah Tosato 43 Pierre-Michel Llorca 44 Paulo Rossi Menezes 45
Craig Morgan39,46 Diego Quattrone11 Marco Menchetti47 Jean-Paul Selten10,48 Andrei Szöke49
Ilaria Tarricone50 Andrea Tortelli51 Philip McGuire5 Lucia Valmaggia52 Matthew J. Kempton5
Mark van der Gaag53 Anita Riecher-Rössler54 Rodrigo A. Bressan 55 Neus Barrantes-Vidal56,57
Barnaby Nelson58,59 Patrick McGorry58,60 Chris Pantelis 60 Marie-Odile Krebs61 Stephan Ruhrmann62
Gabriele Sachs63 Bart P. F. Rutten 10 Jim van Os5,10,64 Behrooz Z. Alizadeh 65,66 Therese van Amelsvoort10
Agna A. Bartels-Velthuis66 Richard Bruggeman66,67 Nico J. van Beveren68,69,70 Jurjen J. Luykx64,71,72
Wiepke Cahn64,73 Claudia J. P. Simons 10,74 Rene S. Kahn 1,75 Frederike Schirmbeck3,6 Ruud van Winkel10,76
EU-GEI High Risk Study Abraham Reichenberg1,2
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
1
Department of Psychiatry, Icahn School of Medicine at Mount
Sinai, New York, NY, USA
2
Seaver Center for Research and Treatment, Icahn School of
Medicine at Mount Sinai, New York, NY, USA
10
Department of Psychiatry and Neuropsychology, School for
Mental Health and Neuroscience, Maastricht University Medical
Centre, Maastricht, The Netherlands
11
Department of Social Genetics and Developmental Psychiatry,
Institute of Psychiatry, Psychology and Neuroscience, King’s
College London, London, England, UK
12
South London and Maudsley NHS Mental Health Foundation
Trust, London, UK
13
Barcelona Clinic Schizophrenia Unit, Neuroscience Institute,
Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS,
Spanish Mental Health Research Network (CIBERSAM),
Barcelona, Spain
3
Department of Psychiatry, Amsterdam UMC, Amsterdam, The
Netherlands
4
Department of Psychiatry, Boston Children’s Hospital, Harvard
Medical School, Boston, MA, USA
5
Department of Psychosis Studies, Institute of Psychiatry,
Psychology and Neuroscience, King’s College London,
London, England, UK
6
Arkin Institute for Mental Health, Amsterdam, The Netherlands
14
7
Department of Neurosciences, Psychiatry Research Group, Center
for Contextual Psychiatry, KU Leuven, Leuven, Belgium
Department of Psychiatry, Yale School of Medicine, New Haven,
CT, USA
15
Mondriaan Mental Health Care, Heerlen/Maastricht, The
Netherlands
16
Faculty of Medicine and Health Sciences - Psychiatry,
Universidad de Oviedo, Mental Health Services of Principado de
Asturias (SESPA), Instituto de Investigacion Sanitaria del
Principado de Asturias (ISPA), INEUROPA, CIBERSAM,
Oviedo, Spain
17
Neurobiological Research Group, Institute of Technology,
Universidad de Castilla-La Mancha, Cuenca, Spain
8
9
Department of Child and Adolescent Psychiatry, Institute of
Psychiatry and Mental Health, Hospital General Universitario
Gregorio Marañón, School of Medicine, Universidad
Complutense, Instituto de Investigación Sanitaria Gregorio
Marañón (IiSGM), Spanish Mental Health Research Network
(CIBERSAM), Madrid, Spain
Mailman School of Public Health, Columbia University,
New York, NY, USA
E. Velthorst et al.
18
Department of Psychiatry, Hospital “Virgen de la Luz”,
Cuenca, Spain
41
PsyLife Group, Division of Psychiatry, UCL, London, England,
UK
19
Universidad de Castilla-La Mancha, Health and Social Research
Center, Cuenca, Spain
42
Department of Biomedicine, Neuroscience and Advanced
Diagnostics, University of Palermo, Palermo, Italy
20
Department of Psychiatry, Hospital Clínico Universitario de
Valencia, INCLIVA, CIBERSAM, School of Medicine,
Universidad de Valencia, Valencia, Spain
43
Section of Psychiatry, Department of Neuroscience, Biomedicine
and Movement, University of Verona, Verona, Italy
44
21
Department of Psychiatry, Instituto de Investigación Sanitaria
(IDIS), Complejo Hospitalario Universitario de Santiago de
Compostela, Santiago de Compostela, Spain
Centre Hospitalier Universitaire de Clermont-Ferrand, ClermontFerrand, France
45
Department of Preventive Medicine, Faculdade de Medicina,
Universidade of São Paulo, São Paulo, Brazil
46
ESRC Centre for Society and Mental Health, King’s College
London, London, UK
47
Department of Biomedical and Neuromotor Sciences, University
of Bologna, Bologna, Italy
48
Rivierduinen Institute for Mental Health Care, Leiden, The
Netherlands
49
INSERM, U955 Créteil, France
Department of Medical and Surgical Sciences, Psychiatry Unit,
Alma Mater Studiorum Università di Bologna, Bologna, Italy
22
23
Grupo de Medicina Xenómica, Fundación Pública Galega de
Medicina Xenómica, Instituto de Investigación Sanitaria de
Santiago de Compostela (IDIS), Galician Health Service
(SERGAS), Santiago de Compostela, Spain
Centro de Investigación en Red de Enfermedades Raras
(CIBERER) y Centro Nacional de Genotipado (CEGEN-PRB3),
Center for Research in Molecular Medicine and Chronic Diseases
(CIMUS), Universidad de Santiago de Compostela, Santiago de
Compostela, Spain
24
Department of Psychiatry, School of Medicine, Ankara
University, Ankara, Turkey
50
25
Department of Psychiatry, Faculty of Medicine, Istanbul
University, Istanbul, Turkey
51
Etablissement Public de Santé Maison Blanche, Paris, France
52
26
Department of Psychiatry, Dokuz Eylül University, School of
Medicine, Izmir, Turkey
Department of Psychology, Institute of Psychiatry, Psychology
and Neuroscience, King’s College London, London, UK
53
27
Department of Neuroscience, Health Sciences Institute, Dokuz
Eylul University, Izmir, Turkey
28
Department of Psychiatry, Adnan Menderes University, School of
Medicine, Aydın, Turkey
Amsterdam Public Mental Health Research Institute, Department
of Clinical Psychology, Faculty of Behavioural and Movement
Sciences, Vrije Universiteit Amsterdam, Amsterdam, The
Netherlands
54
Medizinische Fakultät, Universität Basel, Basel, Switzerland
55
LiNC-Lab Interdisciplinar Neurociências Clínicas, Depto
Psiquiatria, Escola Paulista de Medicina, Universidade Federal de
São Paulo (UNIFESP), São Paulo, Brazil
56
Departament de Psicologia Clínica i de la Salut, Universitat
Autònoma de Barcelona, Barcelona, Spain
57
Fundació Sanitària Sant Pere Claver, Spanish Mental Health
Research Network (CIBERSAM), Barcelona, Spain
58
Orygen, Parkville, VIC, Australia
59
Centre for Youth Mental Health, The University of Melbourne,
Parkville, VIC, Australia
60
Melbourne Neuropsychiatry Centre, Department of Psychiatry,
University of Melbourne & Melbourne Health, Carlton South,
VIC, Australia
61
University of Paris, GHU-Paris, Sainte-Anne, C’JAAD, Inserm
U1266, Institut de Psychiatrie (CNRS 3557), Paris, France
62
Department of Psychiatry and Psychotherapy, Faculty of
Medicine and University Hospital, University of Cologne,
Cologne, Germany
63
Department of Psychiatry and Psychotherapy, Medical University
of Vienna, Vienna, Austria
29
Department of Physiology, School of Medicine, Ankara
University, Ankara, Turkey
30
Brain Research Center, Ankara University, Ankara, Turkey
31
Department of Psychology, Middle East Technical University,
Ankara, Turkey
32
Turkish Federation of Schizophrenia Associations,
Ankara, Turkey
33
Private Practice, Ankara, Turkey
34
Ankara City Hospital Psychiatry Clinic, Ankara, Turkey
35
Faculty of Medicine, University of Belgrade & Institute of Mental
Health, Belgrade, Serbia
36
Faculty of Medicine, University of Belgrade & Clinic for
Psychiatry, Belgrade, Serbia
37
Special Hospital for Psychiatric Disorders Kovin, Kovin, Serbia
38
Ribeirão Preto Medical School, University of São Paulo,
São Paulo, Brazil
39
Department of Health Service and Population Research, Institute
of Psychiatry, King’s College London, London, UK
40
Department of Psychiatry, University of Cambridge,
Cambridge, England, UK
Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders. . .
64
Department of Psychiatry, Brain Centre Rudolf Magnus,
University Medical Center Utrecht, Utrecht University,
Utrecht, The Netherlands
71
Department of Translational Neuroscience, UMC Utrecht Brain
Center, University Medical Center Utrecht, Utrecht University,
Utrecht, The Netherlands
65
Department of Epidemiology, University of Groningen,
University Medical Center Groningen, Groningen, The
Netherlands
72
Outpatient Second Opinion Clinic, GGNet Mental Health,
Apeldoorn, The Netherlands
73
Altrecht Science, Altrecht Mental Health Care, Utrecht, The
Netherlands
74
GGzE Institute for Mental Health Care, Eindhoven, The
Netherlands
75
VISN 2 Mental Illness Research, Education and Clinical Center
(MIRECC), James J. Peters Department of Veterans Affairs
Medical Center, New York, NY, USA
76
Department of Neurosciences, Psychiatry Research Group, Center
for Clinical Psychiatry, KU Leuven, Leuven, Belgium
66
67
University of Groningen, University Medical Center Groningen,
University Center for Psychiatry, Rob Giel Research Center,
Groningen, The Netherlands
Department of Clinical and Developmental Neuropsychology,
University of Groningen, Groningen, The Netherlands
68
Antes Center for Mental Health Care, Rotterdam, The Netherlands
69
Department of Psychiatry, Erasmus MC, Rotterdam, The
Netherlands
70
Department of Neuroscience, Erasmus MC, Rotterdam, The
Netherlands